Form 8-K - Current report:
SEC Accession No. 0001104659-25-118863
Filing Date
2025-12-05
Accepted
2025-12-05 16:02:33
Documents
12
Period of Report
2025-12-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2532811d1_8k.htm   iXBRL 8-K 34217
  Complete submission text file 0001104659-25-118863.txt   202441

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA carm-20251204.xsd EX-101.SCH 3017
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE carm-20251204_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE carm-20251204_pre.xml EX-101.PRE 22360
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2532811d1_8k_htm.xml XML 3698
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 251552899
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)